Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,585 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus, Juvenile-Onset Clear all

Conditions: Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Chronic Kidney Disease, Diabetic Nephropathy Type 2, Kidney Failure, Kidney Insufficiency
Interventions: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose, Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 45 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 1 Diabetes
Interventions: Multisystemic Therapy; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 10 Years to 16 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Diabetes Mellitus, Type 1
Interventions: Otelixizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 16
States / cities: Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 13 more

Conditions: Diabetes Mellitus, Type One, Diabetes Mellitus, Type I, Autoimmune Diabetes, Covid19
Interventions: Bacillus Calmette-Guérin, Saline injection; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2031
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Pramlintide, Exenatide, Insulin; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 12 Years to 21 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Type 1 Diabetes (T1D)
Interventions: Golimumab, Placebo (matching golimumab); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years to 44 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes Mellitus
Interventions: Fear Reduction Intervention, Attention Control; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 35 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes
Interventions: Coin2Dose; Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 11 Years to 17 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Jacksonville, Florida • Kansas City, Missouri

Conditions: Type 1 Diabetes
Interventions: Tandem Automated Insulin Delivery System; Device
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 26 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Type 1 Diabetes Mellitus
Interventions: AP System (DiAs or inControl) with USS Virginia, Sensor-Augmented Pump Therapy (placebo); Device
Lead sponsor: University of Virginia; Other
Eligibility: 12 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Stanford, California • Charlottesville, Virginia

Conditions: Type 1 Diabetes, Diabetes
Interventions: Insulin Efsitora Alfa, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 34
States / cities: Concord, California • Fresno, California • Montclair, California + 27 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Islet Transplant; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: type1diabetes
Interventions: Empagliflozin; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 12 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 1 Diabetes Mellitus
Interventions: LY3209590, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 33
States / cities: Concord, California • Fresno, California • Ventura, California + 29 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Molly Center Diabetes Care Guide (Paper-based), Tablet based interactive diabetes education modules; Other
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: Up to 21 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Type 1 Diabetes
Interventions: CLC + BAM, CLC + ABC; Device
Lead sponsor: Sue Brown; Other
Eligibility: 18 Years to 70 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions: CELZ-201 Administration, Control Group; Biological · Other
Lead sponsor: Creative Medical Technology Holdings Inc; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: I-PORT, standard injections; Device · Other
Lead sponsor: Texas Diabetes & Endocrinology, P.A.; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Type 1 Diabetes (T1D)
Interventions: Cadisegliatin 800 mg QD, Placebo; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes Mellitus
Interventions: Sansum Closed-Loop Artificial Pancreas, Insulin infusion pump, Continuous Glucose Monitor, zone-Model Predictive Control algorithm, Safety Health Monitoring System; Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Type 1 Diabetes
Interventions: Closed-Loop Control System, Sensor-Augmented Pump (SAP); Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 69 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Santa Barbara, California • Stanford, California • Charlottesville, Virginia

Conditions: Type 1 Diabetes Mellitus
Interventions: Boost shake; Dietary Supplement
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 1 Year to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus Type 1
Interventions: iPhone bionic pancreas, iLet bionic pancreas, Xeris Xerisol glucagon, Lilly glucagon, iLet infusion set, Contact Detach infusion set; Device · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes Mellitus
Interventions: Vitamin C, Vitamin E; Dietary Supplement
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 8 Years to 15 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease

Testing MST to Improve Adherence Among Youth With Chronic Poor Metabolic Control

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

A Cognitive Behavioral Therapy (CBT) Intervention to Reduce Fear of Hypoglycemia in Type 1 Diabetes

Coin2Dose: Behavioral Economics to Promote Insulin BOLUS Activity and Improve HbA1c in Teens

Early Automated Insulin Delivery (AID) Pilot for Newly Diagnosed T1D

USS Virginia Closed-Loop Versus SAP Therapy for Hypoglycemia Reduction in T1D

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Islet Transplantation for Type 1 Diabetes Mellitus

Empagliflozin in Adolescent Diabetes

A Study of LY3209590 in Participants With Type 1 Diabetes

Effectiveness of Using Educational Modules Via Bedside Tablet in Newly Diagnosed Type 1 Diabetes

Adaptive Biobehavioral Control (ABC) in a Closed-Loop System

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems

Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS)

Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use

Detection of C-peptide in Youth With Longstanding Type 1 Diabetes Mellitus

The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas

Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes